ovarian Sertoli-Leydig cell tumor

Summary

ovarian Sertoli-Leydig cell tumor (MONDO:0036595) is a cancer and 5 clinical trials. Top therapeutic interventions include paclitaxel, bleomycin sulfate, and etoposide phosphate. A subtype of ovarian sertoli-stromal cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian Sertoli-Leydig cell tumor
Mondo ID	MONDO:0036595
NCIT	C2880
SNOMED CT	254866007
UMLS	C0003810
MedGen	2038
GARD	0027954
Is cancer (heuristic)	yes

Also known as: androblastoma · arrhenoblastoma · ovarian Sertoli-Leydig cell neoplasm · ovarian Sertoli-Leydig cell tumor · Sertoli-Leydig cell tumor of ovary · Sertoli-Leydig cell tumor of the ovary · Sertoli-Leydig cell tumour of ovary · Sertoli-Leydig cell tumour of the ovary · Sertoli-Leydig neoplasm of ovary · Sertoli-Leydig neoplasm of the ovary

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › reproductive system neoplasm › sex cord-stromal tumor › ovarian sex cord-stromal tumor › ovarian sertoli-stromal cell tumor › ovarian Sertoli-Leydig cell tumor

Subtypes (1): malignant Sertoli-Leydig cell tumor of ovary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00006227	PHASE2	COMPLETED	Paclitaxel in Treating Patients With Ovarian Stromal Cancer
NCT00748657	PHASE2	COMPLETED	Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
NCT01042522	PHASE2	UNKNOWN	Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
NCT01247597	Not specified	RECRUITING	DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
NCT00565903	Not specified	COMPLETED	Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PACLITAXEL	4	2
BLEOMYCIN SULFATE	4	1
ETOPOSIDE PHOSPHATE	4	1